Lewis rats immunized with recombinant vaccinia virus expressing the nucleocapsid (N) protein of measles virus were protected from encephalitis when subsequently challenged by intracerebral infection with neurotropic measles virus. Immunized rats revealed polyvalent antibodies to the N protein of measles virus in the absence of any neutralizing antibodies as well as an N protein-specific proliferative lymphocyte response. Depletion of CD8+ T lymphocytes did not abrogate the protective potential of the N protein-specific cell-mediated immune response in rats, while protection could be adoptively transfered with N protein-specific CD4+ T lymphocytes. These results indicate that a CD4+ cell-mediated immune response specific for the N protein of measles virus is sufficient to control measles virus infections of the central nervous system. Measles is a highly contagious disease which can be prevented by a live attenuated measles virus (MV) vaccine. Nevertheless, the infection is not controlled in most parts of the world, and up to two million patients still die annually from measles (20) . Most measles-associated deaths result from bacterial superinfections of the respiratory and gastrointestinal tracts. However, central nervous system (CNS) complications occur in about 1 in 1,000 children and remain a significant cause of permanent neurological morbidity and mortality. In addition, MV is etiologically involved in subacute sclerosing panencephalitis (SSPE), which develops after persistent MV infection in brain tissue (1, 26). Moreover, a rise in measles cases was recently observed in industrialized countries. More than 50% of these measles cases were seen among previously vaccinated patients (5).
Measles is a highly contagious disease which can be prevented by a live attenuated measles virus (MV) vaccine. Nevertheless, the infection is not controlled in most parts of the world, and up to two million patients still die annually from measles (20) . Most measles-associated deaths result from bacterial superinfections of the respiratory and gastrointestinal tracts. However, central nervous system (CNS) complications occur in about 1 in 1,000 children and remain a significant cause of permanent neurological morbidity and mortality. In addition, MV is etiologically involved in subacute sclerosing panencephalitis (SSPE), which develops after persistent MV infection in brain tissue (1, 26) . Moreover, a rise in measles cases was recently observed in industrialized countries. More than 50% of these measles cases were seen among previously vaccinated patients (5) .
While the role of the humoral measles-specific immune response, particularly against the viral hemagglutinin (H) and fusion (F) glycoproteins, for the prevention of measles is well established, little is known about cell-mediated immune (CMI) reactions. Clinical studies have shown that overcoming acute measles requires a competent CMI system to clear the MV infection. Although it was shown that lymphocytes of human high responders can be stimulated to proliferate when cultured in the presence of purified MV H, F, phosphoprotein (P), nucleocapsid (N), and matrix (M) proteins (22) , data are not available about the role of individual MV structural proteins for the induction of CMI reactions and its involvement in acute measles as well as in MV complications of the CNS. The aim of the present study was to investigate the effect of an immune response to the MV N protein expressed by recombinant vaccinia virus (VV) with regard to MV-induced encephalitis in Lewis rats.
MATERIALS AND METHODS
Construction of VV recombinants. VV strain Copenhagen and the temperature-sensitive mutant ts7 (obtained from A. von Depletion of CD8+ T lymphocytes. In order to define which lymphocyte subpopulation restricts virus spread in brain tissue, CD8+ T cells were depleted from animals by an approach similar to that described previously (23) . Starting 1 day before MV infection, rats were injected i.p. on 3 consecutive days with 100 ,ul of mouse ascites containing antibodies directed against the rat CD8 molecule (OX8, immunoglobulin Gl [IgGl] subclass). The efficacy of the antibody treatment was determined retrospectively by fluorescence-activated cell sorting (FACS) analysis in MVNimmunized and MV-infected rats at the end of the experiment, when the animals died or were killed. Superficial cervical lymph nodes were prepared as single-cell suspensions and stained with antibodies against rat T-cell surface molecules, particularly R73 (against o4/3 T-cell receptor [TCR]), W3/25 and OX35 (both CD4 specific), OX8 (CD8 specific), and control OX12 (K chain of immunoglobulin) as well as a monoclonal antibody directed against the S protein of JHM coronavirus (obtained from Helmut Wege, Wurzburg, Germany).
Determination of MV-specific immune response. For determination of humoral immunity, serum samples were taken by tail vein puncture before MV infection and at various intervals thereafter. The titers of antiviral antibodies were determined by an enzyme-linked immunosorbent assay (ELISA) and the MV neutralization test based on plaque reduction as described before (17) . The presence of cytotoxic antibodies was tested by a 51Cr release assay with persistently MV-infected lung fibroblasts as described previously (13) . The specificity of the antiviral antibodies for MV structural proteins was further analyzed by immunostaining of MV that was separated by PAGE prior to Western transfer onto nitrocellulose membranes or by their ability to immunoprecipitate [35S]methionine-labeled MV- infected Vero cell lysates.
The MV-specific cellular immune response in the presence of purified measles virions or N protein was analyzed in cell preparations of lymph nodes from different animals before and after MV infection in a lymphoproliferation assay as described before (16) . Briefly, single-cell suspensions (1 x was determined by the ratio of thymidine incorporation in stimulated versus unstimulated cells and expressed as the stimulation index. When polyclonal lymphocyte populations were assayed, stimulation indices above 2 were considered specific.
CD4+ T-cell lines were isolated from bulk populations by alternating cycles of expansion in interleukin-2 (IL-2)-containing medium and of restimulation with purified MV N protein as described before (15) . The specificity was analyzed in the LPR assay, and the surface phenotype of the cell lines was determined after the third in vitro restimulation by FACS analysis. CD4+ MV N-specific T-cell lines were adoptively transferred during the third or fourth in vitro restimulation-expansion cycle.
MV isolation from brain material. MV replication in the CNS of the animals was assessed by cocultivation of fresh brain material with Vero cells as described before (17) .
Negative results were accepted after 3 weeks with three to four subcultivations.
RESULTS AND DISCUSSION
The entire coding sequence of the N gene of MV strain CAMIR40 was inserted into the thymidine kinase gene of VV-wt strain Copenhagen. Vero cells infected with the recombinant VV-MVN exhibited typical VV plaque morphology and revealed MV N protein in their cytoplasm by indirect immunofluorescence when incubated with MV-specific polyclonal or monoclonal antibodies against the MV N protein (not shown). Immunoprecipitation of "S-labeled VV-MVN-infected Vero cell lysates with serum from a patient with SSPE showed a band corresponding to a 60-kDa protein comigrating with the authentic MV N protein (Fig.  1) .
The immunogenic potential of the recombinant N protein was analyzed by vaccination of Lewis rats with VV-MVN. N-specific T-cell LPR was demonstrable in the polyclonal lymphocyte cultures from spleen and mesenterial lymph nodes 5 days later, and MV-specific serum antibodies were detectable by ELISA with titers in the range of 1:200 to These observations show that the immune response against the N protein of MV expressed by recombinant VV-MVN limits virus spread in the brain and focally restricts the neuropathologic lesions in rats that were infected i.c. with a neurotropic MV strain.
It has been reported previously that recombinant VV expressing the H and F glycoproteins of MV are capable of inducing protective immunity in mice (8) . Since these animals exhibit high levels of virus-neutralizing and/or fusioninhibiting antibodies, it appears likely that the humoral immune response contributes to or is even essential for the protection observed. Moreover, passive transfer of neutralizing antibodies directed against the hemagglutinin of MV modifies the experimental encephalitis in rats, while no such effect could be induced by antibodies with specificity for the MV internal proteins (16) . In the present experiments, however, the cellular immune reaction conceivably plays an essential role, since neutralizing antibodies were not induced in VV-MVN-vaccinated rats (Table 1) . Furthermore, the antinucleocapsid antibodies had no cytotoxic effect on MVinfected cells in a cytotoxic antibody assay (data not shown). These results suggest that, in vivo, activated functional N protein-specific T lymphocytes can effectively travel to MV-infected brain tissue and eliminate virus-infected cells.
In an attempt to find out whether activated CD8+ lympho- cells were eliminated from VV-MVN-immunized rats by injection of monoclonal antibodies directed against the CD8 molecule. Within 24 h of OX8 treatment, CD8+ T cells usually disappear in noninfected rats and cannot be found again for at least 35 days in the superficial cervical or mesenteric lymph nodes (Fig. 2) . By retrospective analysis, 22 VV-MVN-immunized and MV-infected rats were found to be sucessfully and completely depleted of CD8+ lymphocytes and were included in the experiment (Table 3) . Of these animals, seven were killed before day 11 p.i. Of the remaining rats, while 12 showed no symptoms during the 3-week observation period, only 3 developed clinical disease between days 10 and 13 p.i. One died from fatal symptoms by day 11 p.i., while the other two rats recovered and were killed 14 and 16 days after MV infection. MV could not be isolated from the brain tissue of CD8-depleted VV-MVNimmunized rats between 4 and 21 days after MV infection except from two of the three rats that developed clinical symptoms. Histologic examination revealed residual noninflammatory lesions (3 weeks after MV infection) or minor focal encephalitic lesions in the two animals that had recovered from disease as well as in those without symptoms that were killed before day 14 p.i. The changes were not different from those in non-CD8+-cell-depleted protected rats. These results show that CD8+ MV-specific lymphocytes are not a prerequisite for protection from MV-induced encephalitis in rats.
Since depletion or functional inactivation of CD4+ lymphocytes in the rat requires large amounts of antibodies Table 2 , footnote b.
Nineteen of the 22 rats in this group developed no clinical signs and were killed 4 to 21 days after MV infection. Three animals developed neurological symptoms between days 10 and 14 p.i.; two recovered completely and one died on day 11 p.i. MV was isolated from brain tissue of two of the three diseased VV-MVN-immunized rats on days 11 and 14 p.i. Nine rats investigated at 21 days p.i. had residual lesions. Two rats recovering from disease (days 14 and 16 p.i.) as well as 10 rats killed between days 4 and 14 p.i. had mild focal encephalitis. The dead rat showed severe disseminated lesions (day 11 p.i.). (9, 10, 27, 28) . It will be of interest to find out whether similar MHC restrictions occur during MV infection in rat brain.
In our model, the CD4+ lymphocytes apparently function as effectors and restrict MV spread in the brain. A less likely possibility would be that mononuclear phagocytes either resident in the brain or recruited from the peripheral circulation are activated by cytokines secreted from the specific CD4+ lymphocytes to clear the MV from the brain tissue. However, due to the lack of an MV-specific cytotoxic assay in rats, we are not able at present to give a final answer to the question of whether the CD4+ T lymphocytes in the Lewis rat are cytotoxic, as was found for human peripheral blood lymphocytes (12) .
The observation that an immune response to MV N protein controls MV infection of the CNS in the rat model raises the question of why the CMI response fails to eliminate MV in SSPE patients despite the fact that the MV N protein can always be found in infected cells of SSPE patients' brain tissue (14, 20) . So far no specific immunological defects have been seen in SSPE patients which would explain the failure of the host defense mechanism in controlling MV infection. Maybe mutational events of MV genes as a consequence of viral persistence (3, 4) or an impairment of antigen processing and presentation (7) allows the CNS disease process to escape immune system surveillance. Other possible mechanisms include the downregulation of MHC class I and/or II molecules in infected cells (2) and the failure of those cells to express MHC antigens (6) . The latter possibilities could render the major target cells for MV persistence in the human CNS unaccessible to the T-cellmediated immune reactions. Certainly, the animal model will help to define the parameters by which CMI reactions block MV infection in brain tissue. With this information, it may be possible to gain more insight into the pathogenetic mechanisms involved in SSPE and other persistent viral infections of the CNS.
